In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Myasthenia gravis is an antibody-mediated disease of the motor endplate that leads to impaired neuromuscular transmission. 1 Pathogenic antibodies directed against antigens such as the postsynaptic ...

Johnson & Johnson (NYSE: JNJ) has announced promising results from its pivotal Phase 3 Vivacity-MG3 study evaluating ...

Graviss Hospitality Ltd., incorporated in the year 1959, is a Small Cap company (having a market cap of Rs 325.73 Crore) operating in Tourism & Hospitality sector. Graviss Hospitality Ltd. key ...